Buchumschlag

PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hartkopf, Andreas (VerfasserIn) , Taran, Florin-Andrei (VerfasserIn) , Wallwiener, Markus (VerfasserIn) , Walter, Christina B. (VerfasserIn) , Krämer, Bernhard (VerfasserIn) , Grischke, Eva-Maria (VerfasserIn) , Brucker, Sara Y. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: December 8, 2016
In: Breast care
Year: 2016, Jahrgang: 11, Heft: 6, Pages: 385-390
ISSN:1661-3805
DOI:10.1159/000453569
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000453569
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/453569
Volltext
Verfasserangaben:Andreas D. Hartkopf, Florin-Andrei Taran, Markus Wallwiener, Christina B. Walter, Bernhard Krämer, Eva-Maria Grischke, Sara Y. Brucker
Beschreibung
Zusammenfassung:Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
Beschreibung:Gesehen am 30.04.2020
Beschreibung:Online Resource
ISSN:1661-3805
DOI:10.1159/000453569

Ähnliche Einträge